Skip to main content
Erschienen in: Irish Journal of Medical Science (1971 -) 4/2019

28.02.2019 | Original Article

Postoperative thrombotic effects of tranexamic acid in open heart surgery

verfasst von: Ayten Saracoglu, Mehmet Ezelsoy, Kemal Tolga Saracoglu

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Following the administration of tranexamic acid, the occurrence of thromboembolic events is a controversial issue.

Aims

In this retrospective cohort study, we aimed to determine the possible thromboembolic complications due to tranexamic acid as a prophylactic method in patients undergoing open heart surgery.

Methods

The data of 172 adult patients undergoing open heart surgery were analyzed. All patients received tranexamic acid at a dose of 50 mg/kg. The patients were divided into 3 groups as multiple-valve surgery (group 1), coronary bypass alone (group 2), and coronary bypass with valve surgery (group 3). The amount of blood transfusion, bleeding in intra- and postoperative period, and the presence of thromboembolic events including myocardial infarction, stroke, pulmonary embolism, and deep vein thrombosis were investigated.

Results

Patient demographics and duration of surgery were not significantly different in groups (p > 0.05). Hb, Htc, INR, and platelet levels of all groups did not differ significantly (p > 0.05). In total, 7 patients underwent reexploration. Postoperative DVT, stroke, and seizure were not seen at all. There was no statistically significant difference between groups in terms of the amount of blood transfusion, drainage, or peritoneal hematoma. The length of hospital stay and the mortality rate did not differ (p > 0.05).

Conclusions

In patients receiving tranexamic acid infusion at 50 mg/kg dose, reexploration rates remained at 4.1% even after major cardiac surgeries. No thrombosis, stroke, or seizure were reported. Our findings support that tranexamic acid is a safe drug which has positive effect on reducing perioperative bleeding.
Literatur
1.
Zurück zum Zitat Tengborn L, Blombäck M, Berntorp E (2015) Tranexamic acid–an old drug still going strong and making a revival. Thromb Res 135:231–242CrossRef Tengborn L, Blombäck M, Berntorp E (2015) Tranexamic acid–an old drug still going strong and making a revival. Thromb Res 135:231–242CrossRef
2.
Zurück zum Zitat Tang M, Wierup P, Rea CJ, Ingerslev J, Hjortdal VE, Sørensen B (2017) Temporal changes in clot lysis and clot stability following tranexamic acid in cardiac surgery. Blood Coagul Fibrinolysis 28:295–302CrossRef Tang M, Wierup P, Rea CJ, Ingerslev J, Hjortdal VE, Sørensen B (2017) Temporal changes in clot lysis and clot stability following tranexamic acid in cardiac surgery. Blood Coagul Fibrinolysis 28:295–302CrossRef
3.
Zurück zum Zitat Okamoto S, Sato S, Takada Y, Okamoto U (1964) An active stereo-isomer (trans-form) of AMCHA and its antifibrinolytic (antiplasminic) action in vitro and in vivo. Keio J Med 13:177–185CrossRef Okamoto S, Sato S, Takada Y, Okamoto U (1964) An active stereo-isomer (trans-form) of AMCHA and its antifibrinolytic (antiplasminic) action in vitro and in vivo. Keio J Med 13:177–185CrossRef
4.
Zurück zum Zitat Melander B, Gliniecki G, Granstrand B, Hanshoff G (1965) Biochemistry and toxicology of amikapron; the antifibrinolytically active isomer of AMCHA. (A comparative study with epsilon-aminocaproic acid). Acta Pharmacol Toxicol (Copenh) 22:340–352CrossRef Melander B, Gliniecki G, Granstrand B, Hanshoff G (1965) Biochemistry and toxicology of amikapron; the antifibrinolytically active isomer of AMCHA. (A comparative study with epsilon-aminocaproic acid). Acta Pharmacol Toxicol (Copenh) 22:340–352CrossRef
5.
Zurück zum Zitat Hutton B, Joseph L, Fergusson D, Mazer CD, Shapiro S, Tinmouth A (2012) Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network metaanalysis of randomised and observational studies. BMJ 345:e5798CrossRef Hutton B, Joseph L, Fergusson D, Mazer CD, Shapiro S, Tinmouth A (2012) Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network metaanalysis of randomised and observational studies. BMJ 345:e5798CrossRef
6.
Zurück zum Zitat White RH, Zhou H, Romano PS (2010) Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 90:446–455 White RH, Zhou H, Romano PS (2010) Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 90:446–455
7.
Zurück zum Zitat Montroy J, Hutton B, Moodley P et al (2018) The efficacy and safety of topical tranexamic acid: a systematic review and meta-analysis. Transfus Med Rev 19 Montroy J, Hutton B, Moodley P et al (2018) The efficacy and safety of topical tranexamic acid: a systematic review and meta-analysis. Transfus Med Rev 19
8.
Zurück zum Zitat Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, Cooper DJ, Marasco S, McNeil J, Bussières JS, McGuinness S, Byrne K, Chan MT, Landoni G, Wallace S, ATACAS Investigators of the ANZCA Clinical Trials Network (2017) ATACAS investigators of the ANZCA clinical trials network. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med 376:136–148CrossRef Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, Cooper DJ, Marasco S, McNeil J, Bussières JS, McGuinness S, Byrne K, Chan MT, Landoni G, Wallace S, ATACAS Investigators of the ANZCA Clinical Trials Network (2017) ATACAS investigators of the ANZCA clinical trials network. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med 376:136–148CrossRef
9.
Zurück zum Zitat Davidson SJ, McGrowder D, Roughton M, Kelleher AA (2008) Can ROTEM thromboelastometry predict postoperative bleeding after cardiac surgery? J Cardiothorac Vasc Anesth 22:655–661CrossRef Davidson SJ, McGrowder D, Roughton M, Kelleher AA (2008) Can ROTEM thromboelastometry predict postoperative bleeding after cardiac surgery? J Cardiothorac Vasc Anesth 22:655–661CrossRef
10.
Zurück zum Zitat Whiting D, Dinardo JA (2014) TEG and ROTEM: technology and clinical applications. Am J Hematol 89:228–232CrossRef Whiting D, Dinardo JA (2014) TEG and ROTEM: technology and clinical applications. Am J Hematol 89:228–232CrossRef
11.
Zurück zum Zitat Gielen CLI, Brand A, van Heerde WL, Stijnen T, Klautz RJM, Eikenboom J (2016) Hemostatic alterations during coronary artery bypass grafting. Thromb Res 140:140–146CrossRef Gielen CLI, Brand A, van Heerde WL, Stijnen T, Klautz RJM, Eikenboom J (2016) Hemostatic alterations during coronary artery bypass grafting. Thromb Res 140:140–146CrossRef
12.
Zurück zum Zitat Frank SM, Thakkar RN, Podlasek SJ, Ken Lee KH, Wintermeyer TL, Yang WW, Liu J, Rotello LC, Fleury TA, Wachter PA, Ishii LE, Demski R, Pronovost PJ, Ness PM (2017) Implementing a health system-wide patient blood management program with a clinical community approach. Anesthesiology 127:754–764CrossRef Frank SM, Thakkar RN, Podlasek SJ, Ken Lee KH, Wintermeyer TL, Yang WW, Liu J, Rotello LC, Fleury TA, Wachter PA, Ishii LE, Demski R, Pronovost PJ, Ness PM (2017) Implementing a health system-wide patient blood management program with a clinical community approach. Anesthesiology 127:754–764CrossRef
13.
Zurück zum Zitat CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R et al (2010) Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 376:23–32CrossRef CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R et al (2010) Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 376:23–32CrossRef
14.
Zurück zum Zitat Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W (2009) Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res 123:687–696CrossRef Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W (2009) Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res 123:687–696CrossRef
15.
Zurück zum Zitat Gurusamy KS, Pissanou T, Pikhart H et al (2011) Methods to decrease blood loss and transfusion requirements for liver transplantation. Cochrane Database Syst Rev 12:CD009052 Gurusamy KS, Pissanou T, Pikhart H et al (2011) Methods to decrease blood loss and transfusion requirements for liver transplantation. Cochrane Database Syst Rev 12:CD009052
16.
Zurück zum Zitat Adler Ma SC, Brindle W, Burton G, Gallacher S, Hong FC, Manelius I, Smith A, Ho W, Alston RP, Bhattacharya K (2011) Tranexamic acid is associated with less blood transfusion in off-pump coronary artery bypass graft surgery: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth 25:26–35CrossRef Adler Ma SC, Brindle W, Burton G, Gallacher S, Hong FC, Manelius I, Smith A, Ho W, Alston RP, Bhattacharya K (2011) Tranexamic acid is associated with less blood transfusion in off-pump coronary artery bypass graft surgery: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth 25:26–35CrossRef
17.
Zurück zum Zitat Ortmann E, Besser MW, Klein AA (2013) Antifibrinolytic agents in current anaesthetic practice. Br J Anaesth 111:549–563CrossRef Ortmann E, Besser MW, Klein AA (2013) Antifibrinolytic agents in current anaesthetic practice. Br J Anaesth 111:549–563CrossRef
18.
Zurück zum Zitat Thachil J (2016) Disseminated intravascular coagulation–new pathophysiological concepts and impact on management. Expert Rev Hematol 9:803–814CrossRef Thachil J (2016) Disseminated intravascular coagulation–new pathophysiological concepts and impact on management. Expert Rev Hematol 9:803–814CrossRef
19.
Zurück zum Zitat Ghadimi K, Levy JH, Welsby IJ (2016) Perioperative management of the bleeding patient. Br J Anaesth 117:18–30CrossRef Ghadimi K, Levy JH, Welsby IJ (2016) Perioperative management of the bleeding patient. Br J Anaesth 117:18–30CrossRef
20.
Zurück zum Zitat Chakravarthy M, Muniraj G, Patil S et al (2012) A randomized prospective analysis of alteration of hemostatic function in patients receiving tranexamic acid and hydroxyethyl starch (130/0.4) undergoing off pump coronary artery bypass surgery. Ann Card Anaesth 15:105–110CrossRef Chakravarthy M, Muniraj G, Patil S et al (2012) A randomized prospective analysis of alteration of hemostatic function in patients receiving tranexamic acid and hydroxyethyl starch (130/0.4) undergoing off pump coronary artery bypass surgery. Ann Card Anaesth 15:105–110CrossRef
21.
Zurück zum Zitat Bhukar RK, Gowda D, Rao JN, Desai N (2017) Management of atrial thrombus formation following surgical closure of an atrial septal defect. J Card Surg 32:476–478CrossRef Bhukar RK, Gowda D, Rao JN, Desai N (2017) Management of atrial thrombus formation following surgical closure of an atrial septal defect. J Card Surg 32:476–478CrossRef
Metadaten
Titel
Postoperative thrombotic effects of tranexamic acid in open heart surgery
verfasst von
Ayten Saracoglu
Mehmet Ezelsoy
Kemal Tolga Saracoglu
Publikationsdatum
28.02.2019
Verlag
Springer London
Erschienen in
Irish Journal of Medical Science (1971 -) / Ausgabe 4/2019
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-019-01991-z

Weitere Artikel der Ausgabe 4/2019

Irish Journal of Medical Science (1971 -) 4/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.